Common Claim Breadth Issues in Plant- Related Applications Anne Marie Grünberg Supervisory Patent Examiner Art Units 1661 and 1638.

Slides:



Advertisements
Similar presentations
Michael P. Woodward Supervisory Patent Examiner Art Unit 1631 (703) SNiPpetS & Bytes
Advertisements

Michael P. Woodward Supervisory Patent Examiner, Art Unit 1631 (703) Bioinformatics & §101
G & B Seminar 2006 Claim Drafting Ken Moore.
Filing for a United States Patent “Helpful Hints” U.S. Patent and Trademark Office.
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
More on Restriction Practice Jim Housel SPE, Art Unit 1648 (703)
1 Homology Language Brian R. Stanton Quality Assurance Specialist Technology Center 1600 U.S. Patent and Trademark Office (703)
UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the “Notes” Tab. Claim Interpretation: Broadest Reasonable.
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
Claim Interpretation By: Michael A. Leonard II and Jared T. Olson.
“REACH-THROUGH CLAIMS”
1 Biotechnology Partnership Meeting April 17, 2001 James Martinell Senior Level Examiner Technology Center 1600.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
1 Single Nucleotide Polymorphisms (SNP) Gary Jones SPE, Technology Center 1600 (703)
Animals and Transgenesis Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Transgenic Animals — How they are made Examination of Transgenic.
Restriction Practice for Genus Claims Species Claims Linking Claims and Markush Claims Julie Burke QAS/PM TC1600.
Determining Obviousness under 35 USC 103 in view of KSR International Co. v. Teleflex TC3600 Business Methods January 2008.
Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Examining Issues When.
Patent Overview by Jeff Woller. Why have Patents? Patents make some people rich – but, does that seem like something the government should protect? Do.
Issues in Patenting Proteins Jon P Weber, SPE 1657.
Patent Applications Overlapping the Biotechnology and Mechanical Arts THOMAS BARRETT
1 Automated Searching of Polynucleotide Sequences Michael P. Woodward Supervisory Patent Examiner - Art Unit
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
1 Intellectual Property Protection for Plants in the United States Anne Marie Grünberg Supervisory Patent Examiner Art Units 1661 and 1638.
RESTRICTING BETWEEN PRODUCT and PROCESS INVENTIONS Bruce Campell Supervisory Patent Examiner Art Unit
Stem Cells Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Stem Cells — Origin Examination of Stem Cell Claims — Statutes — Sample Claims.
Intellectual Property Protection for Plants in the United States Anne Marie Grünberg Supervisory Patent Examiner Art Units 1661 and 1638.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
COPYRIGHT LAW SPRING 2004 CLASS 4 Professor Fischer Columbus School of Law The Catholic University of America January 28, 2004.
Korean Patent System and Recent Changes. Practices in Chemistry. Bong Sig SONG Korean Patent Attorney Y. S. CHANG & ASSOCIATES February 9 th 2008.
1 ANTICIPATION BY INHERENCY IN PRIOR ART James O. Wilson Supervisory Patent Examiner Technology Center 1600 USPTO (571)
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
1 “In the Examination Process” CLAIM INTERPRETATION.
1 John Calvert Supervisory Patent Examiner
Restriction & Double Patenting Mojdeh Bahar, J.D., M.A., CLP Chief, Cancer Branch Office of Technology Transfer National Institutes of Health U.S. Department.
Impact of Myriad Decisions on Patent Eligibility of Biotechnology Inventions in Australia and the US.
Routine Optimization Jean Witz, tQAS, TC
U.S. Patent and Trademark Office Technology Center 1600 Michael P. Woodward Unity of Invention: Biotech Examples.
Overcoming Prior Art References Non-Enabling Prior Art References Gary Kunz SPE Art Unit 1616.
1 Restriction Practice Updates Julie Burke TC1600 Quality Assurance Specialist
35 U.S.C. 112, Second Paragraph Examination Memorandum Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark.
Josiah Hernandez Patentability Requirements. Useful Having utilitarian or commercial value Novel No one else has done it before If someone has done it.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
Hamre, Schumann, Mueller & Larson, P.C U.S. Patent Claims By James A. Larson.
1 When is it NOT Appropriate to Restrict? Julie Burke TC1600 QAS
Patentability of Reach-Through Claims Brian R. Stanton Practice Specialist Technology Center 1600 (703)
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
1 New Matter Training. 2 Statutes That Govern New Matter  35 USC 112, First Paragraph  The specification shall contain a written description of the.
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice Julie Burke TC1600 Quality Assurance Specialist
Restriction Practice for Combinations and Subcombinations
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
1. 35 USC § 101: Statutory Requirements and Four Categories of Invention August 2015 Office of Patent Legal Administration United States Patent and Trademark.
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
1 Searching in Applications Containing Bio-Sequences Ram R. Shukla Supervisory Patent Examiner Art Unit
(c) 2004, David Schnapf, Sheppard Mullin Richter & Hampton LLP 1 Examiner Use of Background Statements David Schnapf Sheppard Mullin Richter & Hampton.
1 Utility Guidelines, Homology Claims and Anti-Sense Molecule Claims Drew Hissong, Ph.D. dhissong*sughrue.com Sughrue Mion, PLLC
10/13/081 PARK - SPEC SAME IN APP & PAT The Specification: Application v. Issued Patent Why is the specification in the application almost exactly identical.
Processes Which Employ Non-Obvious Products
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
Global Innovation Management Workout on Writing a Patent
Stem Cells Peter Paras, Jr.
Automated Searching of Polynucleotide Sequences
Examination Practice in Applications Presenting “Reach-Through Claims”
Examination Issues: Immunology
Presentation transcript:

Common Claim Breadth Issues in Plant- Related Applications Anne Marie Grünberg Supervisory Patent Examiner Art Units 1661 and 1638

2 Plant Patent vs Plant Utility Patents Plant Patents — One claim, drawn to the plant — Specification can be amended to better describe the plant — Relaxed requirement under 35 U.S.C. 112, first paragraph — No maintenance fees — Reduced examination/search fees Utility Patent to a Plant — Normal utility patents — May have many claims drawn to products or methods — May be broad in scope — May require a deposit to enable

3 Art Unit Examiners 1661 – Plant Patents 1 Expert examiner 5 Primary examiners 1 hybrid classifier/examiner Total = 7 examiners 1638 – Utility Patents 1 Senior examiner 2 PhD examiners 11 Primary examiners 4 Junior examiners Total = 18 examiners

4 Patent Application Stats 1661 – PLTs (1 utility/biweek) — actions 93% allowance rate 1.4 actions per disposal — 2011 to midyear 621 actions 91% allowance rate 1.5 actions per disposal Utility — actions 65% allowance rate 2.5 actions per disposal — 2011 to midyear 1914 actions 66% allowance rate 2.5 actions per disposal

Formal Issues - PLTs Oath/Declaration — Must state that plant was asexually propagated by the applicant — If newly discovered, it must state that the plant was found in a cultivated area Elements of the application missing or not labeled — Missing Latin name of genus and species Claim, Abstract need to be on separate pages 5

6 Common Issues with Plant Patent Applications 35 U.S.C. 112, first and second paragraphs following objection under 37 CFR 1.163(a) — Single claim drawn to a plant (37 CFR 1.164) — 35 U.S.C. 161 description – Description as complete as is reasonably possible — Explicit location of asexual reproduction — Manner of asexual reproduction — Origin of instant plant — Comparison to antecedent and comparitive varieties — Genus and species Latin binomial — Recognized color dictionary/chart — Unsupported colors — Drawings required — Unwarranted advertising — Laudatory expressions — Denomination required

Common Art Issues with PLTs 35 U.S.C. 102 — Same name for same genus and species — 105 Requirement for Information — In re Elsner type 102 — Description lacking – can’t distinguish from prior art 35 U.S.C. 103 — Common methods of manipulating plants Mutation Ploidy level - colchicine 7

Common Rejections made in Utility Applications 35 U.S.C. 101 – statutory subject matter, double patenting, utility 35 U.S.C. 112, second paragraph - indefiniteness 35 U.S.C. 112, first paragraph - enablement, scope of enablement, written description 35 U.S.C. 102 – Novelty 35 U.S.C Obviousness 8

Scope of the Claim Depends on the claim interpretation — Claims must be given their broadest reasonable interpretation consistent with the supporting description (specification) without reading limitations from the specification into the claim (MPEP §2111, In re Hyatt, 54 USPQ2d 1664, 1667 (Fed. Cir. 2000) ) — Words and phrases in claims must be given their “plain meaning” as understood by one having ordinary skill in the art UNLESS such meaning is inconsistent with the specification MPEP §

Claim Interpretation Overall claim interpretation Definition of terms Preamble Transitional phrases 10

Parts of a claim A claim can be broken into parts much like diagramming a sentence. The beginning or introductory phrase of the claim is the “preamble” — May or may not limit the scope of the claim The next “part” is a transitional phrase — “comprising”, “consisting of”, or other like terms — See: MPEP § for more information Finally, the remainder of the claim is referred to as the “body” of the claim 11

Guidance in Determining When a Preamble Will Likely Limit a Claim 1) The preamble is essential to understand limitations or terms in the body of the claim. Pitney Bowes, Inc. v. Hewlett-Packard Co., 51 USPQ2d 1161, (Fed. Cir. 1999). 2) The body of the claim depends on the preamble phrase for antecedent basis. Bell Communications Research, Inc., v. Vitalink Communications Corp., 34 USPQ2d 1816, 1820 (Fed. Cir. 1995). 12

Guidance in Determining When a Preamble Is Not Likely Limit a Claim The body of the claim following the preamble is a self- contained description of the structure and does not depend on the preamble for completeness. A preamble that recites merely the use or purpose of the claimed invention generally does not limit the claims. The preamble merely extols benefits or features of the claimed invention and there is no clear reliance on those benefits or features as patentably significant. (e.g., preamble recites, “[a] head for a lacrosse stick which provides improved handling and playing characteristics.”) 1) Kropa v. Robie, 88 UPSQ at ; IMS Technology Inc. v. Haas Automation Inc., 54 USPQ2d 1129, 1137 (Fed. Cir. 2000). 2) Catalina, 62 USPQ2d at ) STX, LLC v. Brine, Inc., 54 USPQ2d 1347, 1349 (Fed. Cir. 2000). 13

Transitional Phrases Open – comprising, including, containing, characterized by Closed – consisting of Partially Open – consisting essentially of See MPEP

“Wherein” or “Whereby” Clauses A “wherein” clause that merely states the result of the limitations in the claim adds nothing to the patentability or substance of the claim. A “wherein” clause that relates back to and clarifies what is required by the claim and gives meaning and purpose to the claim rather than merely stating inherent results is a limitation that must be given patentable weight. See: MPEP § ; See also Hoffer v. Microsoft Corp., 405 F.3d 1326, 1329, 74 USPQ2d 1481, 1483 (Fed. Cir. 2005). 15

Product By Process Claims Product claim Product defined by the method in which it is made Not limited to the recited steps, only the structure implied by the steps See MPEP 2113, In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985) 16

Claim Analysis with Regard to the Statutes Rejections are generally a function of claim breadth 35 U.S.C. 112, second and fourth 35 U.S.C. 101 product of nature, not statutory, double patenting 35 U.S.C. 112, first, written description and scope of enablement, new matter 35 U.S.C. 102, novelty 35 U.S.C. 103, obviousness 17

What Possible Issues Does Claim 1 Have? Claim 1. Cytochrome P450 protein having an amino acid sequence of SEQ ID NO: I, which originates from Arabidopsis thaliana and can be used for increasing salt tolerance in a plant. What utility does the protein have? Do we know what the protein is? Not “Isolated” – 101, reads on product of nature Second “An” – 102 novelty, reads on as little as 2 amino acids “Originates from” – indefinite, written description, novelty “can be used for” – carries no patentable weight “increasing” – indefinite, relative to what? 18

More Potential Issues? 1. A method for enhancing yield-related traits in plants, comprising introducing and expressing in a plant a nucleic acid encoding a transcription factor, wherein the amino acid sequence of the transcription factor comprises the amino acid sequence of SEQ ID NO: 2 or an orthologue or paralogue thereof, wherein the orthologue or paralogue thereof comprises a motif having at least 70% identity to SEQ ID NO: 4. Note: — SEQ ID NO: 4 is ten amino acids long — SEQ ID NO: 2 is 400 amino acids long 19

Potential Concerns 1. A method for enhancing yield-related traits in plants, comprising introducing and expressing in a plant a nucleic acid encoding a transcription factor, wherein the amino acid sequence of the transcription factor comprises the amino acid sequence of SEQ ID NO: 2 or an orthologue or paralogue thereof, wherein the orthologue or paralogue thereof comprises a motif having at least 70% identity to SEQ ID NO: 4. yield-related traits - indefinite, written description, enablement, orthologue or paralogue – written description, novelty, obviousness at least 70% identity – written description, novelty, obviousness 20

Other Potential Issues? A jalapeño-type chili pepper cultivar having a fruit characterized by a mature seed content of at least 10% less than that of an existing jalapeño-type chili pepper cultivar. Not drawn to a deposited line – enablement, written description, novelty, obviousness What is a jalapeño-type chili pepper? If a pepper is green or has capsaicin, is it a jalapeño-type chili pepper? The comparison is to any pepper? And it only needs to have one fruit that for some reason did not develop seeds? 21

What Possible Concerns Do You See? 1. An isolated polynucleotide comprising: (a) a nucleotide sequence having at least 80% sequence identity to SEQ ID NO:I; (b) a nucleotide sequence encoding a polypeptide having delta-5 desaturase activity, wherein the nucleotide sequence has at least 80% sequence identity to SEQ ID NO:I; or (c) a nucleotide sequence encoding a polypeptide having delta-5 desaturase activity, wherein the nucleotide sequence hybridizes under stringent conditions to a nucleotide sequence as set forth in SEQ ID NO:I. 22

Issues? 1. An isolated polynucleotide comprising: (a) a nucleotide sequence having at least 80% sequence identity to SEQ ID NO:I; (b) a nucleotide sequence encoding a polypeptide having delta-5 desaturase activity, wherein the nucleotide sequence has at least 80% sequence identity to SEQ ID NO:I; or (c) a nucleotide sequence encoding a polypeptide having delta-5 desaturase activity, wherein the nucleotide sequence hybridizes under stringent conditions to a nucleotide sequence as set forth in SEQ ID NO:I. 23

Part (a) - Potential Issues (a) a nucleotide sequence having at least 80% sequence identity to SEQ ID NO:I — Scope of enablement – no functionality for some of the sequences, so how would they be used? — Possible art 24

Part (b) – Potential Issues (b) a nucleotide sequence encoding a polypeptide having delta-5 desaturase activity, wherein the nucleotide sequence has at least 80% sequence identity to SEQ ID NO:I — Written description unless Δ-5 desaturase so well characterized that one would know what domains would need to be retained to have activity — Possible art 25

Part (c) – Potential Issues (c) a nucleotide sequence encoding a polypeptide having delta-5 desaturase activity, wherein the nucleotide sequence hybridizes under stringent conditions to a nucleotide sequence as set forth in SEQ ID NO:I — Written description unless Δ-5 desaturase so well characterized that one would know what domains would need to be retained to have activity — Potential art due to “hybridizes” — Indefinite because it is not clear what hybridizes especially in the face of close prior art — Potential art and written description due to “a” because it reads on small fragments Any coding sequence or cDNA having 20 or so base pair complementarity – perform a score over length oligo search Is hybridization defined or just exemplified? 26

Questions? Anne Marie Grünberg

28 Anne Marie Grunberg holds B.S. and M.S. degrees from the University of Maryland in agronomy with a special emphasis on plant breeding. Her thesis pertained to Amplified Fragment Length Polymorphism (AFLP) markers associated with pre- harvest sprouting in soft red winter wheat. She joined the USPTO in July of 1998 and examined in classes 47, 435, 799 and 800. Anne Marie became a Supervisory Patent Examiner in November, 2005 and received the Department of Commerce Bronze Medal Award in She currently supervises 25 examiners in 2 plant related art units: 1638 and Anne Marie is a veteran of the Unites States Army.